Table 1.
Patient disposition
| Patients enrolled and treated, n | |
| Patients received probe cocktail on day 1 | 16 |
| Patients received guselkumab on day 8 | 14 |
| Patients received probe cocktail on day 15 | 13 |
| Patients received probe cocktail on day 36 | 12 |
| Patients completed study | 12 |
| Reason for discontinuation, n (%) | |
| Adverse event | 1 (6.3) a , b |
| Death | 0 (0.0) |
| Lost to follow‐up | 1 (6.3) a , c |
| Noncompliance with study drug | 0 (0.0) |
| Physician decision (difficulty in blood draw) | 1 (6.3) a , d |
| Pregnancy | 1 (6.3) a , e |
| Protocol violation | 0 (0.0) |
| Study terminated by sponsor | 0 (0.0) |
| Technical problems | 0 (0.0) |
| Withdrawal by patients | 0 (0.0) |
| Product quality complaint | 0 (0.0) |
| Other | 0 (0.0) |
a
The percentage is based on the total number of patients who were enrolled and received probe cocktail administration on day 1.
b
Discontinued on day 17.
c
Discontinued on day 87.
d
Discontinued on day 7.
e
Discontinued on day 20.